REG - Silence Therapeutics - Holding(s) in Company
RNS Number : 7589KSilence Therapeutics PLC06 January 2021
TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i
1a. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached ii:
Silence Therapeutics plc
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)
Non-UK issuer
2. Reason for the notification (please mark the appropriate box or boxes with an "X")
An acquisition or disposal of voting rights
x
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify) iii:
3. Details of person subject to the notification obligation iv
Name
LOIM Lombard Odier Asset Management (Europe) Limited
City and country of registered office (if applicable)
London, United Kingdom
4. Full name of shareholder(s) (if different from 3.) v
Name
City and country of registered office (if applicable)
5. Date on which the threshold was crossed or reached vi:
04/01/2021
6. Date on which issuer notified (DD/MM/YYYY):
05/01/2021
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A)
% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)
Total of both in % (8.A + 8.B)
Total number of voting rights of issuer vii
Resulting situation on the date on which threshold was crossed or reached
10.96%
1.94%
12.90%
83,306,259
Position of previous notification (if applicable)
12.80%
0.21%
13.01%
ISIN CODE (if possible)
GB00B9GTXM62 Ordinary
SUBTOTAL 8. A
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type of
shares
ISIN CODE (if possible)
Number of voting rights ix
% of voting rights
Direct(Art 9 of Directive 2004/109/EC) (DTR5.1) Indirect(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
Direct(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
GB00B9GTXM62 Ordinary
9,130,523
10.96%
SUBTOTAL 8. A
9,130,523
10.96%
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial
instrument
Expiration
date x
Exercise/
Conversion Period xi
Number of voting rights
that may be acquired if
the instrument is
exercised/converted.
% of voting rights
ADR US82686Q1013
1,620,000
1.94%
SUBTOTAL 8. B 1
1,620,000
1.94%
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrument
Expiration date x
Exercise/
Conversion Period xi
Physical or cash settlement xii
Number of voting rights
% of voting rights
CASH
SUBTOTAL 8.B.2
9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an "X")
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii
x
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity xiv (please add additional rows as necessary)
Name xv
% of voting rights if it equals or is higher than the notifiable threshold
% of voting rights through financial instruments if it equals or is higher than the notifiable threshold
Total of both if it equals or is higher than the notifiable threshold
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional information xvi
Place of completion
London
Date of completion
05/01/2021
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDHOLUNRRRAVUARAR
Recent news on Silence Therapeutics
See all newsREG - AIM - Cancellation - Silence Therapeutics Plc
AnnouncementREG - Silence Therapeutics - Update on AIM Delisting
AnnouncementREG - FTSE Russell Silence Therapeutics Serica Energy PLC Pantheon Resources - Silence Therapeutics
AnnouncementREG - Silence Therapeutics - Third Quarter 2021 Financial Results
AnnouncementREG - Silence Therapeutics - Silence to Present at Jefferies London Conference
Announcement